ArticleVeterinary sciences2025
TLR Agonist Immunoadjuvants Provide Effective Protection Against PCV2 and PRV Infections in a Bivalent Subunit Vaccine for PCV2 and PRV.
Article in Veterinary sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A lipid nanoparticle-based mRNA vaccine elicits immunity against porcine circovirus type 2 in mice.Microbiology spectrum · 2026Article
- Knowledge gaps in research and control of porcine circovirus 2 (PCV2) infections.BMC veterinary research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diseases associated with porcine circovirus type 2 (PCV2) and pseudorabies virus (PRV) significantly affect the economy of pig farms, particularly when combined infections lead to bacterial co-infections. Antigens from the pseudorabies variant strain gB and gD proteins and PCV2 (genotyped) Cap protein were mixed with the pattern recognition receptor (PRR) agonist FLICd as adjuvants and formulated with a micro-hydrogel adjuvant into PCV2 and PRV bivalent subunit vaccines. Twenty pigs, aged 30-35 days, were divided into groups A (received bivalent subunit vaccine) and B (received bivalent subunit vaccines with recombinant FLICd adjuvant), as well as C (non-vaccinated challenge control) and D (blank control). Groups A and B showed no significant difference in average daily weight gain compared to the unvaccinated controls. Fourteen days post-second vaccination, groups A and B exhibited significantly higher levels of PRV and PCV2 antibodies than groups C and D. Group B showed significantly higher average titers of PRV-specific neutralizing antibodies than group A. Fourteen days post-second vaccination, a PRV (ZJM-1 strain) challenge test was conducted. The vaccinated group achieved 100% protection. Vaccination effectively reduced virus load post-challenge and shortened the PRV shedding period. Vaccination with PCV2 and PRV bivalent subunit vaccines effectively prevents the onset of PCV2-related diseases and infections by wild pseudorabies strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.